These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 29155997)

  • 1. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
    Panda A; Mehnert JM; Hirshfield KM; Riedlinger G; Damare S; Saunders T; Kane M; Sokol L; Stein MN; Poplin E; Rodriguez-Rodriguez L; Silk AW; Aisner J; Chan N; Malhotra J; Frankel M; Kaufman HL; Ali S; Ross JS; White EP; Bhanot G; Ganesan S
    J Natl Cancer Inst; 2018 Mar; 110(3):316-320. PubMed ID: 29155997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability.
    Almhanna K; Antonia S
    J Natl Cancer Inst; 2018 Mar; 110(3):221-222. PubMed ID: 29155933
    [No Abstract]   [Full Text] [Related]  

  • 3. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
    Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
    Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review.
    Bos J; Groen-van Schooten TS; Brugman CP; Jamaludin FS; van Laarhoven HWM; Derks S
    Cancer Treat Rev; 2024 Jun; 127():102737. PubMed ID: 38669788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors.
    Iwasaki A; Shinozaki-Ushiku A; Kunita A; Yamazawa S; Sato Y; Yamashita H; Fukayama M; Seto Y; Ushiku T
    Am J Surg Pathol; 2021 Sep; 45(9):1213-1220. PubMed ID: 34310369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
    Derks S; Liao X; Chiaravalli AM; Xu X; Camargo MC; Solcia E; Sessa F; Fleitas T; Freeman GJ; Rodig SJ; Rabkin CS; Bass AJ
    Oncotarget; 2016 May; 7(22):32925-32. PubMed ID: 27147580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer.
    Dai C; Geng R; Wang C; Wong A; Qing M; Hu J; Sun Y; Lo AW; Li J
    Mol Oncol; 2016 Dec; 10(10):1551-1558. PubMed ID: 27720576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
    Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection.
    Chiaravalli AM; Feltri M; Bertolini V; Bagnoli E; Furlan D; Cerutti R; Novario R; Capella C
    Virchows Arch; 2006 Mar; 448(3):344-53. PubMed ID: 16261379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
    Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
    Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
    Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
    Nakano H; Saito M; Nakajima S; Saito K; Nakayama Y; Kase K; Yamada L; Kanke Y; Hanayama H; Onozawa H; Okayama H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Goto A; Kono K
    Sci Rep; 2021 Jan; 11(1):1982. PubMed ID: 33479394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
    Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?
    Moore A; Hikri E; Goshen-Lago T; Barkan T; Morgenstern S; Brook E; Maderer A; Roth W; Gordon N; Kashtan H; Brenner B; Moehler M; Aharon IB
    BMC Cancer; 2020 Jan; 20(1):34. PubMed ID: 31937281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.